col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

31 Results       Page 1

Elsevier: Medicine in Drug Discovery
  original article Date Title Authors   All Authors
1 [GO] 2022―Nov―09 Deciphering antiviral efficacy of malaria box compounds against malaria exacerbating viral pathogens- Epstein Barr Virus and SARS-CoV-2, an in silico study Omkar Indari, Ajit Kumar Singh, Deeksha Tiwari, Hem Chandra Jha, Anupam Nath Jha
2 [GO] 2022―Jun―13 Liposome encapsulated clodronate mediated elimination of pathogenic macrophages and microglia: A promising pharmacological regime to defuse cytokine storm in COVID-19 Sowbarnika Ravichandran, Nivethitha Manickam, Mahesh Kandasamy
3 [GO] 2021―Dec―04 The Delta Variant Mutations in the Receptor Binding Domain of SARS-CoV-2 Show Enhanced Electrostatic Interactions with the ACE2 Shaimaa S. Goher, Fedaa Ali, Muhamed Amin
4 [GO] 2021―Aug―06 Liposomes and mRNA: two technologies together create a COVID-19 vaccine Gregory Gregoriadis
5 [GO] 2021―May―25 Antiviral performance of graphene-based materials with emphasis on COVID-19: A review Tahereh Seifi, Ali Reza Kamali
6 [GO] 2021―Mar―30 Network bioinformatics analysis provides insight into drug repurposing for COVID-19 Xu Li, Jinchao Yu, Zhiming Zhang, Jing Ren, Alex E Peluffo, Wen Zhang, et al. (+5)
7 [GO] 2021―Mar―19 New threatening of SARS-CoV-2 co-infection and strategies to fight the current pandemic Nikky Goel, Razi Ahmad, Huma Fatima, Sunil Kumar Khare
8 [GO] 2021―Mar―11 The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review Subham Das, K.R. Anu, Sumit Birangal, Saleem Akbar, Bahar Ahmed, Alex Joseph
9 [GO] 2021―Mar―02 The new SARS-CoV-2 strain shows a stronger binding affinity to ACE2 due to N501Y mutant Fedaa Ali, Amal Kasry, Muhamed Amin
10 [GO] 2020―Dec―24 AI drug discovery screening for COVID-19 reveals zafirlukast as a repurposing candidate Marcin Delijewski, Jacek Haneczok
11 [GO] 2020―Oct―20 Protein-driven mechanism of multiorgan damage in COVID-19 Ernesto Estrada
12 [GO] 2020―Sep―18 Serum levels of Vitamin C and Vitamin D in a cohort of critically ill COVID-19 patients of a North American Community Hospital Intensive Care Unit in May 2020. A Pilot Study Cristian Arvinte, Maharaj Singh, Paul E. Marik
13 [GO] 2020―Jul―24 Viral sepsis is a complication in patients with Novel Corona Virus Disease (COVID-19) Di Liu, Qiang Wang, Huacai Zhang, Li Cui, Feng Shen, Yong Chen, et al. (+9)
14 [GO] 2020―Jul―16 Cyclophilin A and CD147: novel therapeutic targets for the treatment of COVID-19 Chenglong Liu, Di Zhu
15 [GO] 2020―Jun―19 ET-traps as a potential treatment for COVID-19 Arjun Jain, Vidhi Mehrotra
16 [GO] 2020―Jun―05 Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19 B. Solun, Y. Shoenfeld
17 [GO] 2020―Jun―02 Can We Reduce Mortality of COVID-19 if We do Better in Glucose Control? Mingyan Deng, Ling Jiang, Yan Ren, Jiayu Liao
18 [GO] 2020―Jun―02 Vitamin D Levels and COVID-19 Susceptibility: Is there any Correlation? Karan Razdan, Kuldeep Singh, Dilpreet Singh
19 [GO] 2020―May―27 BCG vaccination strategy implemented to reduce the impact of COVID-19: Hype or Hope? Keshav Rajarshi, Aroni Chatterjee, Shashikant Ray
20 [GO] 2020―May―15 COVID-19 lockdown: de-risking exit by protecting the lung with leukaemia inhibitory factor (LIF) Su M. Metcalfe
21 [GO] 2020―May―11 Melatonin Inhibits COVID-19-induced Cytokine Storm by Reversing Aerobic Glycolysis in Immune Cells: A Mechanistic Analysis Russel J. Reiter, Ramaswamy Sharma, Qiang Ma, Alberto Dominquez-Rodriguez, Paul E. Marik, Pedro Abreu-Gonzalez
22 [GO] 2020―Apr―29 Perspectives for the use of therapeutic Botulinum toxin as a multifaceted candidate drug to attenuate COVID-19 Mahesh Kandasamy
23 [GO] 2020―Apr―29 Does vitamin D status impact mortality from SARS-CoV-2 infection? Paul E. Marik, Pierre Kory, Joseph Varon
24 [GO] 2020―Apr―19 PAK1-blockers: Potential Therapeutics against COVID-19 Hiroshi Maruta, Hong He
25 [GO] 2020―Apr―13 Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies Jiayu Liao, George Way, Vipul Madahar
26 [GO] 2020―Apr―09 Meeting the Potential Emergency Global Drug Supply Challenge of Hydroxychloroquine for COVID-19 Tony Y. Zhang, Boyu Zhong
27 [GO] 2020―Apr―04 The role of afferent pulmonary innervation in poor prognosis of acute respiratory distress syndrome in COVID-19 patients and proposed use of resiniferatoxin (RTX) to improve patient outcomes in advanced disease state: A review Alexis Nahama, Roshni Ramachandran, Alvaro Francisco Cisternas, Henry Ji
28 [GO] 2020―Apr―03 Standing out from the crowd in treating COVID-19 Kim D. Janda, Michael J. Iadarola
29 [GO] 2020―Mar―26 Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19)? Richard Z. Cheng
30 [GO] 2020―Mar―25 Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus Henry Ji, Ying Yan, Beibei Ding, Wenzhong Guo, Mark Brunswick, Andreas Niethammer, et al. (+4)
31 [GO] 2020―Mar―19 Mesenchymal stem cells and management of COVID-19 pneumonia Su M. Metcalfe

31 Results       Page 1


Last change 2022―Feb―03 17:06:14 UTC

© Daten-Quadrat 2022       Done in 0.016 sec